Fox Run Management’s Iovance Biotherapeutics IOVA Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,015	Closed	-$80.3K	–	945
2024 Q2	$80.3K	Buy	+10,015	New	+$107K	0.02%	731
2024 Q1	–	Sell	-22,712	Closed	-$185K	–	924
2023 Q4	$185K	Buy	22,712 +6,633	+41%	+$34.7K	0.05%	641
2023 Q3	$73.2K	Buy	+16,079	New	+$105K	0.02%	646
2022 Q4	–	Sell	-17,419	Closed	-$167K	–	755
2022 Q3	$167K	Buy	+17,419	New	+$201K	0.07%	506
2022 Q2	–	Sell	-17,380	Closed	-$289K	–	635
2022 Q1	$289K	Buy	17,380 +4,918	+39%	+$76.1K	0.16%	285
2021 Q4	$238K	Buy	12,462 +427	+4%	+$9.4K	0.14%	307
2021 Q3	$297K	Buy	+12,035	New	+$284K	0.19%	233
2020 Q3	–	Sell	-7,670	Closed	-$211K	–	247
2020 Q2	$211K	Buy	+7,670	New	+$252K	0.28%	199
2020 Q1	–	Sell	-11,878	Closed	-$329K	–	244
2019 Q4	$329K	Buy	+11,878	New	+$270K	0.26%	151
2018 Q2	–	Sell	-13,713	Closed	-$232K	–	790
2018 Q1	$232K	Buy	+13,713	New	+$208K	0.06%	582